VCN

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Retrieved on: 
Monday, March 25, 2024
Research, SJD, IDMC, Conference call, Conference, Retinoblastoma, Telephone, Patient, Acquisition, Cancer, VCN, Insurance, Bank statement, GMP, Clinical trial, Safety, Sant Joan, Therapy, Intravenous therapy, HCT, Pharmaceutical industry

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full-year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The trial is expected to enroll 92 evaluable patients and remains on track to complete enrollment in H1 2024.
  • Other income for the year ended December 31, 2023 is primarily comprised of interest income of $1,439,000 and an exchange gain of $3,000.
  • Cash and cash equivalents totaled $23.2 million as of December 31, 2023, compared to $41.8 million as of December 31, 2022.
  • ET to discuss its financial results for the full-year ended December 31, 2023 and provide a corporate update.

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Monday, November 13, 2023
Durvalumab, Neck, Research, NYSE, Shield, GMP, Safety, Telephone, Head, Conference call, Clinical trial, ESMO, HCT, Patient, FDA, Cancer, VCN, Therapy, Conference, University, SITC, Survival, Congress, CPS, KOL, ICO, Travel, University of Pennsylvania, Pharmaceutical industry, Cryptocurrency, PDAC

ET -

Key Points: 
  • ET -
    ROCKVILLE, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Third Quarter Ended September 30, 2023 Financial Results
    General and administrative expenses decreased to $212,000 for the three months ended September 30, 2023, from $2.4 million for the three months ended September 30, 2022.
  • Theriva Biologics will host a conference call on Monday, November 13, 2023, at 8:30 a.m.
  • ET to discuss its financial results for the quarter ended September 30, 2023 and provide a corporate update.

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

Retrieved on: 
Monday, December 11, 2023
Huachung University, Multiple myeloma, Triple, Ophthalmology, HKEX, Safety, SAN, Hope, Treatment, Progression-free survival, ASH, Risk, Tongji Hospital station, Tongji Medical College, Patient, PFS, MRD, Marketing, Trial of the century, Medicine, VCN, Prognosis, Peking Union Medical College, ORR, Cancer, Survival, RRMM, BCMA, Quality of life, Society, Autoimmunity, Pharmaceutical industry, Medical device, Vaccine, Hematology

The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.

Key Points: 
  • The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.
  • As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients.
  • Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%.
  • Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative.

Economist Impact and Infosys launch the Value Chain Navigator to help businesses manage and mitigate their scope 3 emissions

Retrieved on: 
Thursday, October 5, 2023
BSE, Investment, NYSE, Sustainability, Value, Science Based Targets initiative, INFY, Resource, Transport, Resource and Energy Economics, Public utility, The Economist Group, Carbon, Economist, NSE, Carbon accounting, VCN, EVP, Research, Science, Renewable energy, Infosys

LONDON, Oct. 5, 2023 /PRNewswire/ -- Economist Impact, an arm of The Economist Group that works with organisations globally to further their missions, and Infosys (NSE, BSE, NYSE: INFY), a global leader in next-generation digital services, today announced the launch of the Value Chain Navigator (VCN) to help businesses understand and address their scope 3 emissions.

Key Points: 
  • Scope 3 includes all indirect emissions that occur in the upstream and downstream activities of an organisation's value chain.
  • Up to 95% of a business's carbon footprint consists of scope 3 emissions, but only a quarter of businesses account for them in their net zero plans.
  • Technological innovations can help businesses monitor, manage and reduce emissions in their upstream and downstream value chains.
  • Our work with Infosys to create The Sustainability Project and now, the Value Chain Navigator, exemplifies the impact we can make in the world."

Economist Impact and Infosys Launch the Value Chain Navigator to Help Businesses Manage and Mitigate their Scope 3 Emissions

Retrieved on: 
Thursday, October 5, 2023
BSE, Investment, NYSE, Sustainability, Value, Science Based Targets initiative, INFY, Resource, Transport, Resource and Energy Economics, Public utility, The Economist Group, Carbon, Economist, NSE, Carbon accounting, VCN, EVP, Research, Science, Renewable energy, Infosys

Scope 3 includes all indirect emissions that occur in the upstream and downstream activities of an organisation's value chain.

Key Points: 
  • Scope 3 includes all indirect emissions that occur in the upstream and downstream activities of an organisation's value chain.
  • Up to 95% of a business's carbon footprint consists of scope 3 emissions, but only a quarter of businesses account for them in their net zero plans.
  • Technological innovations can help businesses monitor, manage and reduce emissions in their upstream and downstream value chains.
  • Our work with Infosys to create The Sustainability Project and now, the Value Chain Navigator, exemplifies the impact we can make in the world."

Economist Impact and Infosys Launch the Value Chain Navigator to Help Businesses Manage and Mitigate their Scope 3 Emissions

Retrieved on: 
Thursday, October 5, 2023
BSE, Investment, NYSE, Sustainability, Value, Science Based Targets initiative, INFY, Resource, Transport, Resource and Energy Economics, Public utility, The Economist Group, Carbon, Economist, NSE, Carbon accounting, VCN, EVP, Research, Science, Renewable energy, Infosys

Scope 3 includes all indirect emissions that occur in the upstream and downstream activities of an organisation's value chain.

Key Points: 
  • Scope 3 includes all indirect emissions that occur in the upstream and downstream activities of an organisation's value chain.
  • Up to 95% of a business's carbon footprint consists of scope 3 emissions, but only a quarter of businesses account for them in their net zero plans.
  • Technological innovations can help businesses monitor, manage and reduce emissions in their upstream and downstream value chains.
  • Our work with Infosys to create The Sustainability Project and now, the Value Chain Navigator, exemplifies the impact we can make in the world."

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Tuesday, August 8, 2023
GMP, Travel, IV, Senior, Shield, Telephone, Survival, Head, Teaching hospital, Congress, Biomedical Research Institute, Acquisition, Patient, NYSE, Texas Biomedical Research Institute, VCN, Brain, University, Therapy, Cancer, Immunotherapy, Coronavirus Scientific Advisory Board, Research, University of Pennsylvania, FDA, Safety, Pancreatic cancer, ESMO, ICO, HCT, CAR, Ovarian cancer, ST, Clinical trial, Neck, ET, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical imaging, Cryptocurrency, PDAC, Discovery, U.S

ET -

Key Points: 
  • ET -
    ROCKVILLE, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
  • These results build on the impressive safety, biochemical and mechanistic data presented last year, demonstrating that VCN-01 improved tumor immunogenicity in previously immunotherapy refractory patients.
  • Second Quarter Ended June 30, 2023 Financial Results
    General and administrative expenses increased to $2.7 million for the three months ended June 30, 2023, from $1.5 million for the three months ended June 30, 2022.
  • ET to discuss its financial results for the quarter ended June 30, 2023 and provide a corporate update.

Workspaces for Oracle: Click-2-Subscribe - Revolutionizing Digital Workplaces through the Enterprise Browser

Retrieved on: 
Tuesday, June 27, 2023
Cloud, Workforce, VCN, CDI, Partnership, Oracle Linux, Workspace, Organization, Containerization, Cloud Infrastructure Management Interface, Risk, Oracle Cloud, OCI, Software, Online shopping, Asset management, Oracle

MCLEAN, Va., June 27, 2023 /PRNewswire/ -- Kasm Technologies, a leading provider of secure browser-based workspace solutions, in partnership with Oracle, is thrilled to announce the general availability of Workspaces for Oracle: Click-2-Subscribe. This groundbreaking platform empowers organizations with a vendor-managed browser security solution, redefining the way digital workspaces are accessed and secured. By reducing exposure to vulnerable hardware and compromised networks, organizations can ensure enhanced security and minimize risk.

Key Points: 
  • This groundbreaking platform empowers organizations with a vendor-managed browser security solution, redefining the way digital workspaces are accessed and secured.
  • Private Registry & Custom Workspaces – Establish custom workspaces with software tailored to your specific needs and hosted in an OCI private registry.
  • Leveraging Oracle Cloud Infrastructure's next-generation capabilities, organizations can establish highly secure and scalable digital workplaces that contribute to a sustainable future.
  • Learn more about how Kasm Workspaces Containerized Desktop Infrastructure (CDI) is powering the Workspaces for Oracle offering: https://oracle.kasmweb.com/

Canada’s First Compound Fertilizer Manufacturing Facility to Supply Domestic, Export Markets

Retrieved on: 
Wednesday, June 14, 2023
VCN, Farmer, Fertilizer, Nutrient, Nitrous oxide, Climate change, Soil, St. Lawrence Seaway, Climate, Health, Food security, Potash, Atlantic Ocean

MAITLAND, Ontario, June 14, 2023 (GLOBE NEWSWIRE) -- Vanguard Crop Nutrition Inc. ( VCN Canada ) has begun construction on a first-of-its-kind compound fertilizer manufacturing facility in Maitland, Ontario.

Key Points: 
  • MAITLAND, Ontario, June 14, 2023 (GLOBE NEWSWIRE) -- Vanguard Crop Nutrition Inc. ( VCN Canada ) has begun construction on a first-of-its-kind compound fertilizer manufacturing facility in Maitland, Ontario.
  • “There is no better time than now to build and safeguard Canada’s manufacturing and supply of next-generation crop nutrition solutions,” said Ryan Brophy, VCN Canada’s CEO.
  • VCN Canada will onshore the manufacturing of multi-nutrient compound fertilizers, previously made in Eastern Europe and imported to Canada and the Americas.
  • The site will begin production of already commercially available compound fertilizers ELEVEN Superstart, and soon-to-be-launched Soy7 MAX and Pulse8.

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

Retrieved on: 
Tuesday, May 23, 2023
VCN, Therapy, Senior, Shield, ICO, Cancer, Immunotherapy, Lead, United States Air Force Scientific Advisory Board, Catalan Institute of Nanoscience and Nanotechnology (ICN2), Biomedical Research Institute, Acquisition, Immune system, Potyvirus, Growth, Entrepreneurship, Neoplasm, NYSE, Pharmaceutical industry, Vaccine, Discovery

ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the appointment of Dr. Ramon Alemany as Senior Vice President of Discovery, effective immediately. Dr. Alemany will oversee Theriva’s discovery and development pipeline and will continue to serve as Chair of the Scientific Advisory Board.

Key Points: 
  • ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the appointment of Dr. Ramon Alemany as Senior Vice President of Discovery, effective immediately.
  • Dr. Alemany will oversee Theriva’s discovery and development pipeline and will continue to serve as Chair of the Scientific Advisory Board.
  • “Ramon is an internationally recognized expert in oncolytic adenoviruses and as Co-Founder of VCN Biosciences, is uniquely suited to lead Theriva’s discovery program through its next critical phase of development,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • Combining novel viral payloads with the proprietary Albumin Shield technology to protect systemically administered oncolytic viruses from the host immune system has tremendous potential for our pipeline.”